National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts.org
Search Results

This is VAERS ID 1338273

Government Disclaimer on use of this data

History of Changes from the VAERS Wayback Machine

First Appeared on 7/9/2021

VAERS ID: 1338273
VAERS Form:2
Age:
Sex:Male
Location:Foreign
Vaccinated:2020-10-01
Onset:2021-04-13
Submitted:0000-00-00
Entered:2021-05-21
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / 1 - / OT
UNK: VACCINE NOT SPECIFIED (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK - / OT

Administered by: Other      Purchased by: ??
Symptoms: Computerised tomogram, Heart rate, Subarachnoid haemorrhage, Angiotensin converting enzyme, Scan brain, Blood test, Coma scale, Blood pressure measurement

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:2021-04-18
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? Yes
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: ROSUVASTATIN; ACEBUTOLOL; KARDEGIC; PERINDOPRIL; PERMIXON; TARDYFERON; PANTOPRAZOLE; CALCIUM LEVOFOLINATE; FLUOROURACILE
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Adenocarcinoma of colon (Hepatic metastatic colonic adenocarcinoma); Arterectomy (TAVI with arterial resection in 2019); Benign prostatic hyperplasia; Cholecystectomy; Drug allergy (Allergies: EFFERALGAN); Extracorporeal shock wave lithotripsy (2 extracorporeal lithotripsy); Gastrectomy total (for MALT lymphoma in 1996); Hepatic cancer metastatic (Hepatic metastatic colonic adenocarcinoma); Hypertension arterial; Ischaemic heart disease; MALT lymphoma; Metastases to lung (Lieberkuhnien adenocarcinoma diagnosed with synchronous hepatic and pulmonary metastases.); Penicillin allergy; Skin carcinoma (Epithelial carcinomas of the scalp); TAVI (TAVI with arterial resection in 2019); Triple vessel bypass graft (Triple coronary artery bypass surgery in 2012); Urinary calculus (Urinary lithiasis (2 extracorporeal lithotripsy))
Allergies:
Diagnostic Lab Data: Test Name: angiotensin-converting enzyme; Result Unstructured Data: Test Result:929; Test Name: angiotensin-converting enzyme; Result Unstructured Data: Test Result:56; Test Date: 20210413; Test Name: Blood pressure; Result Unstructured Data: Test Result:168/77; Comments: Upon arrival of the Emergency medical assistance service; Test Date: 20210413; Test Name: blood bradykinin concentration; Result Unstructured Data: Test Result:unknown results; Comments: Upon arrival of the Emergency medical assistance service; Test Date: 20210413; Test Name: Glasgow Coma Scale; Result Unstructured Data: Test Result:7; Comments: Upon arrival of the Emergency medical assistance service; Test Name: Computed tomography scan; Result Unstructured Data: Test Result:diminution of the hepatic lesions with thoracic st; Comments: diminution of the hepatic lesions with thoracic stability; Test Date: 20210413; Test Name: Computed tomography scan; Result Unstructured Data: Test Result:Emergency cerebral computed tomography: Fisher 4 s; Comments: Emergency cerebral computed tomography: Fisher 4 sub-arachnoid haemorrhage with damage to the left temporal horn and significant intracranial hypertension.; Test Date: 20210413; Test Name: heart rate; Result Unstructured Data: Test Result:98; Comments: Upon arrival of the Emergency medical assistance service; Test Date: 20210413; Test Name: Cerebral scan; Result Unstructured Data: Test Result:Predominantly peri-mesencephalic meningeal haemorr; Comments: Predominantly peri-mesencephalic meningeal haemorrhage, and in the occipital cortical sulci. Tetra-ventricular hematic flooding leading to upstream hydrocephalus with early transependymal resorption disorders. No aneurism seen in the Willis polygon arteries. Mesencephalic oedema.
CDC 'Split Type': FRPFIZER INC2021553668

Write-up: Subarachnoid hemorrhage; This is a spontaneous report from a contactable physician downloaded from the regulatory authority-WEB, regulatory authority number FR-AFSSAPS-SE20211054 , Safety Report Unique Identifier FR-AFSSAPS-2021052754.Telephone declaration on 29Apr2021, medically confirmed. An 85-year-old male patient received bnt162b2 (COMIRNATY), dose 1 intramuscular on 22Mar2021 (Batch/Lot number was not reported) as 1ST DOSE, SINGLE for covid-19 immunisation; bevacizumab (ZIRABEV), intravenous (IV) drip from 01Oct2020 (Batch/Lot number was not reported) to 08Apr2021, at 5 mg/kg, frequency as every14 days for adenocarcinoma of colon. The patient''s medical history included hypertension arterial; MALT (mucosa-associated lymphoid tissue) lymphoma; Ischaemic heart disease; Benign prostatic hyperplasia; Urinary lithiasis (2 extracorporeal lithotripsy); Epithelial carcinomas of the scalp; Hepatic metastatic colonic adenocarcinoma. Surgeries history also reported Total gastrectomy for MALT lymphoma in 1996; Cholecystectomy in 2006; Triple coronary artery bypass surgery in 2012; and TAVI with arterial resection in 2019. Patient has allergies to PENICILLIN and "EFFERALGAN ?" (Toxic: 0). COVID-19 HISTORY: patient was at risk of developing a severe form of COVID-19, patient was with no history of COVID-19, it was unknown if patient had been tested for COVID-19. ONCOLOGY HISTORY: in Jul2020, Lieberkuhnien adenocarcinoma diagnosed with synchronous hepatic and pulmonary metastases; On 07Sept2020, Multidisciplinary Oncology Digestive meeting: Indication of first chemotherapy of a bio-chemical type plus biotherapy according to the complete molecular biology, then re-evaluation of the surgical project secondarily; On 18Jan2021, Multidisciplinary Oncology Digestive meeting: Assessment after 6 treatments with FOLFOX AVASTIN, significant hypertension and AVASTIN stopped at treatment 5 despite treatment adjustments. Weight loss with poor state of health despite the adapted dosage. Drop in angiotensin-converting enzyme to 56 compared to 929. Computed tomography scan = diminution of the hepatic lesions with thoracic stability. Proposition of maintenance therapy with 5FU hormone therapy. Discussion of reintroduction of BEVACIZUMAB depending on pressure balance; Last chemotherapy treatment on 08Apr2021: Response after 6 treatments with FOLFOX AVASTIN but poor state of health and improved hypertension after dose was adapted. Currently: maintenance with 5Fu plus Bevacizumab with Treatment 1: 11Feb2021, Treatment 2: 25Feb2021, Treatment 3: 11Mar2021, Treatment 4: 25Mar2021, Treatment 5: 08Apr2021. Cure composed of: ZIRABEV (bevacizumab): 5mg/kg, Calcium Levofolinate: 200mg/m?, and Fluorouracile: 400mg/m? slow intravenous plus 2400 mg/m? via mobile diffuser. The patient''s concomitant medications included rosuvastatin 5mg: 0-0-1; acebutolol 200mg: 0.5-0-0; acetylsalicylate lysine (KARDEGIC) 75mg: 0-1-0; perindopril 8mg: 0-0-1; serenoa repens extract (PERMIXON) 160mg: 1-0-1; ferrous sulfate (TARDYFERON) 1-0-0; pantoprazole 20mg: 1-0-0; calcium levofolinate 200mg/m?; and fluorouracil (FLUOROURACILE) 400mg/m? slow intravenous + 2400 mg/m? via mobile diffuser. The patient experienced subarachnoid hemorrhage on 13Apr2021 which resulted in death. The description of the effect and detailed clinical course was follows: On 13Apr2021, treated by the Emergency medical assistance service for neurological issues in a context of metastatic rectal cancer being treated with chemotherapy. Context of balance issues since the previous day (12Apr2021). Last contact with the patient yesterday at 23:00. Patient found at home in a coma since at least this morning. No evidence of a fall or head injury. Upon arrival of the Emergency medical assistance service: Glasgow Coma Scale 7, left hemiparesis with + blood bradykinin concentration. Blood pressure: 168/77. HR: 98. Emergency cerebral computed tomography: Fisher 4 sub-arachnoid haemorrhage with damage to the left temporal horn and significant intracranial hypertension; Neurosurgeon opinion: no surgical evidence or indication selected. IMAGING: Cerebral scan on 13Apr2021: Predominantly peri-mesencephalic meningeal haemorrhage, and in the occipital cortical sulci. Tetra-ventricular hematic flooding leading to upstream hydrocephalus with early transependymal resorption disorders. No aneurism seen in the Willis polygon arteries. Mesencephalic oedema; Urgent neurosurgeon opinion. PROGRESS: patient transferred to the palliative care unit. Death on 18Apr2021. CONCLUSION: patient presented with a meningeal haemorrhage at Day 23 from Dose 1 of COMIRNATY, in a context of chemotherapy for a metastatic adenocarcinoma with treatment 5 of bevacizumab 10 days earlier. The patient died on 18Apr2021. The cause of death was reported as subarachnoid hemorrhage. It was unknown if an autopsy was performed. The outcome of the other events besides subarachnoid hemorrhage was unknown. No follow-up attempts possible. No further information expected. Batch/lot number cannot be obtained.; Reported Cause(s) of Death: Subarachnoid hemorrhage

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=1338273&WAYBACKHISTORY=ON


Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166